Novo Nordisk

Novo Nordisk has appointed Edward L. Williams vice president of biopharmaceuticals and a member of the executive team. In this position, Mr. Williams will build and execute the business strategies for the biopharmaceuticals business unit and will set direction for the company’s biopharmaceutical products, including hemostasis, growth hormone therapy, and hormone therapy for women.

Mr. Williams brings 26 years of industry experience to Novo Nordisk. Most recently, he served as vice president of sales for the respiratory and dermatology business unit at Novartis Pharmaceuticals where he managed the commercial growth of several products.

As vice president of biopharmaceuticals, he will expand the biopharmaceutical product portfolio and execute strategies to ensure continued profitability and sustainability. He also will lead efforts to explore the full potential of the company’s biopharmaceuticals projects as well as identify new drug targets. He will also focus on putting the correct structure, processes, and support in place to strengthen the company’s marketing, sales, and medical affairs departments. Mr. Williams will report directly to Martin Soeters, president of Novo Nordisk.